Company Filing History:
1 out of 197 
1 out of 306 
1 out of 6 Years Active: 1989-1990
Title: Gerhard Rauber: Innovator in the Treatment of Hyperuricaemia
Introduction
Gerhard Rauber, located in Ingelheim am Rhein, Germany, is a noted inventor with significant contributions to the field of pharmaceuticals. With three patents to his name, his innovative work centers on developing well-tolerated drugs for treating hyperuricaemia, a condition that can lead to gout and kidney stones.
Latest Patents
Among his latest patents is the significant work on "Use of oxoquinazoline derivatives in the treatment of hyperuricaemia." These oxoquinazoline derivatives, detailed in his patent specifications, are formulated in such a way that they provide effective treatment options for patients suffering from this condition. Notably, these drugs have proven to be well-tolerated, emphasizing their potential for widespread medical application.
Career Highlights
Throughout his career, Gerhard Rauber has been affiliated with prominent organizations, including Boehringer Ingelheim KG and Boehringer Ingelheim GmbH. His tenure at these companies has allowed him to engage deeply in research and development, translating innovative ideas into practical pharmaceutical solutions.
Collaborations
Rauber has collaborated closely with various professionals in his field, including his coworker Roland Stechert. These collaborations have facilitated a productive exchange of ideas and have been instrumental in advancing their shared goals in innovative drug development.
Conclusion
Gerhard Rauber's contributions to the treatment of hyperuricaemia highlight the importance of innovation in pharmaceuticals. His work exemplifies the significant impact that dedicated inventors can have on healthcare, providing solutions that improve the quality of life for many patients. Through his patents and collaborations, Rauber continues to be a key figure in the field of pharmaceutical inventions.